[go: up one dir, main page]

WO2016071770A3 - Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same - Google Patents

Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same Download PDF

Info

Publication number
WO2016071770A3
WO2016071770A3 PCT/IB2015/002303 IB2015002303W WO2016071770A3 WO 2016071770 A3 WO2016071770 A3 WO 2016071770A3 IB 2015002303 W IB2015002303 W IB 2015002303W WO 2016071770 A3 WO2016071770 A3 WO 2016071770A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cell lymphoma
mantle cell
patients
identifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2015/002303
Other languages
French (fr)
Other versions
WO2016071770A2 (en
Inventor
Sriram Balasubramanian
Michael Schaffer
Aleksandra RIZO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of WO2016071770A2 publication Critical patent/WO2016071770A2/en
Publication of WO2016071770A3 publication Critical patent/WO2016071770A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Disclosed herein are methods of predicting a likelihood of responsiveness to treatment with ibrutinib in a patient having mantle cell lymphoma and methods of treating a patient having mantle cell lymphoma.
PCT/IB2015/002303 2014-11-05 2015-11-05 Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same Ceased WO2016071770A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462075544P 2014-11-05 2014-11-05
US62/075,544 2014-11-05

Publications (2)

Publication Number Publication Date
WO2016071770A2 WO2016071770A2 (en) 2016-05-12
WO2016071770A3 true WO2016071770A3 (en) 2016-08-11

Family

ID=55221449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/002303 Ceased WO2016071770A2 (en) 2014-11-05 2015-11-05 Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same

Country Status (1)

Country Link
WO (1) WO2016071770A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141044A1 (en) 2015-03-04 2016-09-09 Arizona Board Of Regents On Behalf Of Arizona State University Erbb4 inhibitors and methods of use thereof
WO2018200505A1 (en) * 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013059738A2 (en) * 2011-10-19 2013-04-25 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
WO2016019341A1 (en) * 2014-08-01 2016-02-04 Pharmacyclics Llc Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
WO2016022853A1 (en) * 2014-08-08 2016-02-11 Pharmacyclics Llc Bruton's tyrosine kinase inhibitor combinations and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013059738A2 (en) * 2011-10-19 2013-04-25 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
WO2016019341A1 (en) * 2014-08-01 2016-02-04 Pharmacyclics Llc Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
WO2016022853A1 (en) * 2014-08-08 2016-02-11 Pharmacyclics Llc Bruton's tyrosine kinase inhibitor combinations and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AILEEN NOVERO ET AL: "Ibrutinib for B cell malignancies", EXPERIMENTAL HEMATOLOGY & ONCOLOGY, BIOMED CENTRAL LTD, LONDON, UK, vol. 3, no. 1, 28 January 2014 (2014-01-28), pages 4, XP021176524, ISSN: 2162-3619, DOI: 10.1186/2162-3619-3-4 *
AMIN AALIPOUR ET AL: "Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas", BRITISH JOURNAL OF HAEMATOLOGY, vol. 163, no. 4, 24 September 2013 (2013-09-24), GB, pages 436 - 443, XP055153751, ISSN: 0007-1048, DOI: 10.1111/bjh.12573 *
ANDREW M. INTLEKOFER ET AL: "Precision therapy for lymphoma-current state and future directions", NATURE REVIEWS CLINICAL ONCOLOGY, vol. 11, no. 10, 1 January 2014 (2014-01-01), NY, US, pages 585 - 596, XP055263742, ISSN: 1759-4774, DOI: 10.1038/nrclinonc.2014.137 *
BALASUBRAMANIAN SRIRAM ET AL: "78: Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)", vol. 124, no. 21, 1 December 2014 (2014-12-01), pages Abstr.78, XP008179755, ISSN: 0006-4971, Retrieved from the Internet <URL:http://www.bloodjournal.org/content/124/21/78> *

Also Published As

Publication number Publication date
WO2016071770A2 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
WO2016054520A3 (en) Engineered cell surface proteins and uses thereof
EP3229586A4 (en) Genetically modified cells, tissues, and organs for treating disease
IL282627A (en) Anaerobic blood storage and pathogen inactivation method
WO2016037157A3 (en) Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
IL257105A (en) Adapted cells and treatment methods
ZA201802351B (en) Electrode system, device and method for the treatment of eye diseases, in particular dry eye
EP3077933B8 (en) Computational medical treatment plan method and system with mass medical analysis
PL2870913T3 (en) Device for the extraction, storage and/or treatment of blood or other substances of human or animal origin, and for the use of blood compounds or other biological compounds
EP3632378C0 (en) DEVICE WITH REDUCED CARDIAC PACEMAKER RATE IN HEART VALVE REPLACEMENT
WO2016085632A3 (en) Microfluidic measurements of the response of an organism to a drug
SG10201902594QA (en) Peptidomimetic macrocycles and uses thereof
MX382337B (en) GLOBIN GENE THERAPY AND ITS USE FOR THE TREATMENT OF HEMOGLOBINOPATHIES.
EP3054954A4 (en) Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin&#39;s lymphoma
WO2014138429A3 (en) Peptidomimetic macrocycles and use thereof in regulating hif1alpha
PT2945642T (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
EP3154533A4 (en) Methods of anesthetizing nerve tissue in the trigeminal nerve pathway and medical uses thereof
GB201207585D0 (en) An electrode and use thereof
DK3065764T6 (en) Mini-gastrin analog, particularly for use in CCK-2 receptor positive tumor diagnosis and/or treatment
EP3200118A4 (en) Sample traceability device and method for medical research and/or diagnosis
BR112014027905A2 (en) antibody, cell, nucleic acid, methods of identifying a first antibody, inhibiting cell growth, therapeutic treatment, determining the presence of a protein, diagnosing a tumor, and delivering a cytotoxic agent.
EP3176130A4 (en) Treatment device, sterilization device, sterilization water, and sterilization method
WO2014107718A3 (en) Heat shock protein (hsp) inhibition and monitoring effectiveness thereof
EP3474868A4 (en) Manipulated cardiac muscle cells and uses thereof
EP3101117A4 (en) Biological tissue cutting device and use thereof
WO2016071770A3 (en) Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15828369

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15828369

Country of ref document: EP

Kind code of ref document: A2